| Authors: |
Borcoman E; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.; INSERM U932, Immunity and Cancer, Institut Curie, Paris, France.; Translational Immunotherapy Team, Translational Research Department, Institut Curie, Paris, France.; Université Paris Sciences Lettres (PSL), Paris, France., Cabarrou B; Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud, Toulouse, France., Francisco M; INSERM U900, Institut Curie, Mines Paris Tech, Paris, France.; Paris-Saclay University, Paris, France., Bigot F; Institut de Cancérologie de l'Ouest, Angers, France., Ghiringhelli F; Centre Georges-François Leclerc, Dijon, France., Vansteene D; Institut de Cancérologie de l'Ouest, Saint-Herblain, France., Legrand F; Unicancer, Paris, France., Halladjian M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Dupain C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Le Saux O; Medical Oncology, Centre Léon Berard, Lyon, France., Coutzac C; Medical Oncology, Centre Léon Berard, Lyon, France., Borel C; Centre Paul Strauss, Strasbourg, France., Chaltiel R; Institut Godinot, Reims, France., You B; Medical Oncology, CITOHL, EPSILYON, IC-HCL, Lyon University Hospital (HCL), University Lyon 1, Lyon, France., Gomez-Roca C; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France., Cousin S; Institut Bergonié, Bordeaux, France., Coquan E; Centre François Baclesse, Caen, France., Lambert A; Institut de Cancerologie de Lorraine, Vandœuvre-Lès-Nancy, France., Saada-Bouzid E; Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.; Laboratory of Translational Research in Oncology, Cote D'Azur University, Nice, France., Durando X; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France., Saint-Ghislain M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Frige G; Experimental Oncology, Instituto Europeo di Oncologia, Milan, Italy., Guerini-Rocco E; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, European University of Milan, Milan, Italy., Tonini MM; Translational Medicine Operations Hub, Luxembourg Institute of Health, Strassen, Luxembourg., Bièche I; Department of Genetics, Institut Curie, Paris, France., Castel-Ajgal Z; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Marret G; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Sablin MP; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Jeannot E; Department of Pathology, Institut Curie, Paris, France., Andre F; Gustave Roussy, Villejuif, France., Filleron T; Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud, Toulouse, France., Jimenez M; Unicancer, Paris, France., Mazzarella L; Laboratory of Translational Oncology, European Institute of Oncology IRCCS, Milano, Italy.; Division of Gatrointestinal Oncology, European Institute of Oncology IRCCS, Milano, Italy.; Division of Advanced Molecular Diagnostics (DIMA), European Institute of Oncology IRCCS, Milano, Italy., Servant N; INSERM U900, Institut Curie, Mines Paris Tech, Paris, France., Kamal M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France. christophe.letourneau@curie.fr.; INSERM U900, Institut Curie, Mines Paris Tech, Paris, France. christophe.letourneau@curie.fr.; Paris-Saclay University, Paris, France. christophe.letourneau@curie.fr. |
